MART-1 Immunostaining in Melanoma Mohs

---

Evidence Snapshot

• MART-1 frozen section achieves 95.3% sensitivity and 95.1% specificity for melanoma detection during Mohs surgery
• Local recurrence rate: 0.49% for primary melanomas treated with Mohs using MART-1 (vs. 9–20% with conventional wide excision)
• 5-year disease-specific survival: 98.53% with Mohs-MART-1 approach
• MART-1 is the preferred immunostain for frozen sections due to superior sensitivity, crisp staining, consistency, and minimal background
• Tissue-preserving margins possible: ~82% of melanomas completely excised with ≤6 mm margins, ~97% with ≤12 mm

---

What Is MART-1 (Melan-A) Immunostaining?

MART-1, also known as Melan-A (Melanoma Antigen Recognized by T cells 1), is a monoclonal antibody that specifically recognizes a cytoplasmic antigen expressed by melanocytes and melanoma cells. In the context of Mohs micrographic surgery, MART-1 immunostaining of frozen sections dramatically improves the surgeon's ability to identify melanoma cell margins intraoperatively, enabling real-time assessment and precise margin control.

Why MART-1 Matters:

Traditional hematoxylin and eosin (H&E) staining of frozen sections relies on morphologic criteria and can be challenging in several clinical scenarios:

• Melanoma in situ (MIS) on sun-damaged skin is difficult to distinguish from atypical melanocytic hyperplasia with H&E alone
• Frozen section cellular detail is inferior to permanent sections, limiting morphologic assessment
• Desmoplastic melanoma may appear subtle on H&E frozen sections
• Thin, early invasive melanomas can be missed on frozen H&E

MART-1 immunostaining provides a crisp, specific visualization of melanocytic proliferation, essentially "lighting up" the tumor margins so the surgeon can identify the exact extent of disease intraoperatively. This transforms margin assessment from subjective morphology to objective immunochemistry.

---

How Does Frozen Section Mohs Differ from Permanent Section Processing?

Frozen Section Processing (Intraoperative, Real-Time)

Timeline: Approximately 20–60 minutes from tissue excision to stain interpretation, depending on protocol complexity.

Procedure:

1. Fresh tissue is immediately embedded in optimal cutting temperature (OCT) medium
2. Tissue is snap-frozen at –20°C to –30°C in a cryostat
3. Thin sections (8–10 micrometers) are cut on a cryostat microtome
4. Frozen sections are mounted on glass slides
5. Immunohistochemical staining is applied (MART-1 protocol, see below)
6. Slides are examined under a light microscope by the Mohs surgeon

Advantages:

• Immediate results (same-day surgery)
• Intact epithelial-dermal junction for proper margin assessment
• Allows real-time decision-making and staged tissue removal
• Superior for margin-oriented cases

Limitations:

• Cellular detail inferior to permanent sections (artifact from freezing)
• Background staining may occasionally occur
• Some antigens may be disrupted by freezing
• Requires on-site staining capability

Permanent Section Processing (Delayed, Reference Standard)

Timeline: 3–7 days for processing, paraffin embedding, sectioning, and staining.

Procedure:

1. Fresh tissue is placed in neutral buffered formalin (NBF)
2. Tissue is processed through graded alcohols and cleared in xylene
3. Tissue is embedded in paraffin wax
4. Sections are cut at 4–5 micrometers on a rotary microtome
5. Routine H&E or immunohistochemical staining is performed
6. Pathologist reviews slides under microscope

Advantages:

• Superior cellular morphology (no freezing artifact)
• Crisp nuclear detail and better color resolution
• Standard reference for diagnostic confirmation
• Allows for additional stains if needed

Limitations:

• Delayed diagnosis (not useful for intraoperative margin assessment)
• Paraffin embedding causes tissue shrinkage and distortion
• Cannot guide real-time surgical decision-making

Clinical Application: In Mohs-MART-1 practice, frozen sections guide intraoperative margin assessment, and permanent sections provide diagnostic confirmation and staging. A concordance rate of 96.8% has been reported between frozen MART-1 and subsequent permanent section interpretation.

---

Technical Methodology: The MART-1 Immunostaining Protocol

Antibody Selection

Primary Antibody:

• Clone: Melan-A/MART-1 (preferably A103 or equivalent clone)
• Source: Mouse monoclonal
• Optimal Concentration: 1:80–1:400 dilution (varies by manufacturer and antibody lot)
• Why This Clone: A103 provides superior sensitivity and crisp cytoplasmic staining with minimal background compared to other clones

Validation: Each new lot of antibody should be validated on known positive control tissue (normal skin with melanocytes, benign nevi, melanoma) before clinical use.

Antigen Retrieval

Key Consideration: Frozen sections contain well-preserved antigens and generally do not require aggressive antigen retrieval as used in paraffin sections.

Standard Frozen Section Protocol:

1. Air Drying: Allow slides to air dry for 15–30 minutes at room temperature to improve tissue adhesion
2. Light Fixation: Fix in 10% neutral buffered formalin (NBF) for 1–3 minutes (brief, mild fixation)
3. Rinsing: Rinse in phosphate-buffered saline (PBS) for 2–3 minutes
4. Optional Antigen Enhancement:
   • Some protocols use brief heat-based antigen retrieval (microwave or pressure cooker, 95–100°C for 2–5 minutes)
   • Others omit antigen retrieval entirely for frozen sections
   • Clinical protocols vary; choose based on laboratory validation

Step-by-Step Staining Protocol

Materials Needed:

• Frozen section slides (8–10 μm thickness on glass slides)
• Primary antibody (MART-1/Melan-A, A103 clone)
• Secondary antibody (horse anti-mouse, typically HRP-conjugated)
• Blocking serum (10% normal horse serum or equivalent)
• Diaminobenzidine (DAB) chromogen substrate
• Light microscopy supplies

Protocol:

1. Blocking (10 minutes)

   • Apply normal blocking serum (horse or appropriate species)
   • Incubate at room temperature
   • Prevents non-specific antibody binding

2. Primary Antibody Incubation (30–60 minutes at room temperature, or overnight at 4°C)

   • Apply diluted primary MART-1 antibody (typically 1:100–1:200)
   • Incubate in humidified chamber
   • Longer incubation times improve sensitivity

3. Rinsing (3–5 minutes)

   • Rinse slides in PBS (3 changes, 1–2 minutes each)
   • Remove excess primary antibody

4. Secondary Antibody Incubation (30–45 minutes at room temperature)

   • Apply HRP (horseradish peroxidase)-conjugated secondary antibody
   • Incubate in humidified chamber
   • Typical dilution: 1:200–1:500

5. Rinsing (3–5 minutes)

   • Rinse in PBS (3 changes, 1–2 minutes each)
   • Remove excess secondary antibody

6. DAB Chromogen Development (5–15 minutes)

   • Apply DAB substrate
   • Brown color develops at sites of HRP activity
   • Monitor visually; stop reaction when desired intensity is achieved
   • Typically 5–10 minutes; over-staining (loss of detail) or under-staining (weak signal) should be avoided

7. Rinsing and Counterstaining (3–5 minutes)

   • Rinse slides in distilled water
   • Apply light hematoxylin counterstain (1–2 minutes)
   • Rinse again
   • Blue nuclei provide morphologic reference

8. Mounting

   • Allow slides to air dry
   • Mount with aqueous or permanent mounting medium
   • Apply coverslip

Expected Results:

• Melanocytes and melanoma cells: brown cytoplasmic staining
• Epidermal keratinocytes (benign): no staining (or occasional weak staining in rare cases)
• Dermal fibroblasts and other cells: no staining
• Nuclei (hematoxylin counterstain): blue

Rapid 20-Minute Protocol

A rapid MART-1 protocol has been developed in high-volume Mohs centers to accelerate intraoperative results:

Modifications for Speed:

• Omit formal antigen retrieval (frozen sections not required to process)
• Reduce blocking time to 5 minutes
• Use concentrated primary antibody (1:50–1:100) with 15–20 minute incubation
• Use pre-conjugated secondary-HRP antibody (35% Systems or equivalent single-step system) for 10 minutes
• Optimize DAB development to 5–8 minutes

Result: Can achieve full staining and interpretation in 20–30 minutes total, enabling true same-day Mohs surgery with comprehensive margin assessment.

---

Clinical Decision-Making: When to Use MART-1 vs. H&E Alone

Use MART-1 Immunostaining When:

Clinical Scenario 1: Melanoma In Situ on Chronically Sun-Damaged Skin

• Challenge: Histologic distinction between MIS and atypical melanocytic hyperplasia (AMH) is notoriously difficult
• H&E Limitations: Overlapping cytologic features, variable maturation of melanocytes, difficulty determining true nevic vs. dysplastic
• MART-1 Advantage: Highlights increased melanocyte density and distribution; clarifies the extent of intraepidermal melanocytic proliferation
• Clinical Action: Strongly recommend MART-1 for all MIS cases, especially trunk and head/neck

Clinical Scenario 2: Desmoplastic Melanoma

• Challenge: Sparse melanocytes surrounded by collagen desmoplasia; can be nearly invisible on H&E frozen sections
• H&E Limitations: Melanocytes may not be apparent, leading to underestimation of extent
• MART-1 Advantage: Makes sparse melanocytes readily visible; crucial for accurate margin assessment
• Clinical Action: MART-1 is essential for desmoplastic and neurotropic melanomas

Clinical Scenario 3: Thin Invasive Melanoma

• Challenge: Early vertical growth phase; subtle invasion; morphology difficult to assess on frozen section
• H&E Limitations: Frozen section artifact; difficulty distinguishing invasive cells from intraepidermal component
• MART-1 Advantage: Clearly delineates extent of melanocytic proliferation; helps identify invasive component
• Clinical Action: MART-1 recommended for all invasive melanomas, even if thin

Clinical Scenario 4: Large Field Cancerization Areas

• Challenge: Extensive field of dysplastic melanocytes; difficult to map extent with H&E alone
• H&E Limitations: Patchy, difficult-to-define margins; risk of missing peripheral islands
• MART-1 Advantage: Uniform staining of entire melanocytic proliferation; clearly shows extent and continuity
• Clinical Action: MART-1 critical for comprehensive margin mapping

When Standard H&E Frozen Section May Be Sufficient:

• Thick, obviously invasive melanomas with well-defined borders
• Nodular melanomas with clear demarcation from surrounding skin
• Cases where cost is a limiting factor and Mohs surgeon has extensive experience with H&E interpretation
• Institutional expertise in H&E frozen section interpretation of melanoma exceeds other centers

Important Note: If margins appear unclear on H&E, immediately add MART-1 immunostaining rather than re-excising. The small additional time investment provides tremendous diagnostic confidence.

---

False Positive Considerations: Melanocytic Hyperplasia vs. Melanoma In Situ

The Diagnostic Challenge

One of the most common pitfalls in melanoma Mohs is false-positive interpretation of benign melanocytic proliferations as melanoma, or conversely, false-negative misses of subtle MIS.

MART-1 Staining Patterns: Benign vs. Malignant

Feature	Benign Melanocytic Hyperplasia	Melanoma In Situ
Density of Staining	Mild to moderate, often uniform	Increased, often patchy or irregular
Distribution Pattern	Usually organized along basement membrane, sparse higher in epidermis	Scattered throughout epidermis, often ascends to superficial layers
Adnexal Extension	May involve adnexal epithelium, but organized	Abnormal extension far down adnexae; marked density
Cytologic Atypia (H&E)	Minimal; cytologically benign melanocytes	Nuclear enlargement, hyperchromasia, irregular contours
Maturation	Clearly present; cells smaller/lighter with depth	Poor maturation; cells remain dark and atypical with depth
Pagetoid Spread	Absent or minimal	Present; scattered melanocytes throughout epithelium

Critical Interpretation Points

Context is King:

• Clinical scenario matters: chronically sun-damaged face = high risk for MIS
• History of dysplastic nevi or prior melanoma = lower threshold for calling MIS
• Patient age and Fitzpatrick skin type influence prevalence of each entity

Morphology Should Accompany Immunostain:

• MART-1 is a sensitivity tool, not a specificity tool
• Always correlate MART-1 positivity with H&E morphology
• Use MART-1 to identify areas to scrutinize for cytologic atypia, not as sole diagnostic criterion

Common Pitfall—"Junctional Hyperplasia":

• Normal skin and sun-damaged skin contain benign melanocytic proliferations
• These may show mild MART-1 positivity
• Distinguish from MIS by absence of cytologic atypia and orderly distribution

---

Comparison Table: H&E vs. MART-1 vs. SOX10 vs. Other Markers

Feature	H&E Alone	MART-1 Immunostain	SOX10	S-100	HMB-45	MEL-5
Sensitivity (Frozen)	85–90%	95.3%	90–95%	95–98%	70–85%	85–90%
Specificity (Frozen)	85–90%	95.1%	80–90%	80–90%	90–95%	85–90%
Background Staining	N/A (H&E)	Minimal	Moderate	Moderate–High	Low	Low–Mod
Crisp Staining Pattern	Morphologic	Excellent	Good	Variable	Good	Good
Cost	Low (routine stain)	Moderate	Moderate	Moderate	Moderate	High
Speed (Frozen Section)	Immediate	20–60 min	30–60 min	30–60 min	30–60 min	30–60 min
Artifact in Frozen Sections	Moderate	Minimal	Minimal	Minimal	Minimal	Minimal
Desmoplastic Melanoma Detection	Poor	Excellent	Excellent	Excellent	Poor	Good
Usefulness in MIS vs. AMH Distinction	Limited	Excellent	Good	Good	Poor	Moderate
Clinical Adoption	Universal	Widely adopted	Emerging	Traditional	Specialty use	Specialty use
Best Clinical Application	Any case (baseline)	Standard choice for MMS	Alternative/adjunct	Educational/research	Adjunct for MIS	Specialty cases

Interpretation Notes

MART-1 vs. SOX10:

• Both have excellent sensitivity
• MART-1 provides crisper, cleaner staining with less background
• SOX10 also stains nerve sheath cells (useful for perineural assessment)
• Most centers use MART-1 as primary marker; SOX10 reserved for specific scenarios

MART-1 vs. S-100:

• S-100 is more sensitive but less specific (stains neural elements, cartilage, etc.)
• MART-1 is more melanoma-specific with equivalent sensitivity
• S-100 useful for traditional dermatopathology; MART-1 preferred for Mohs

HMB-45:

• Less sensitive in frozen sections
• Better for permanent section diagnosis of deep dermal vs. junctional components
• Not recommended as primary marker for Mohs frozen sections

MEL-5 and Other Markers:

• Primarily research tools or specialty applications
• Limited clinical adoption in routine Mohs practice

---

Frozen Section Concordance with Permanent Section

Accuracy of MART-1 Frozen Section vs. Permanent Section Pathology

A prospective cohort study evaluated accuracy of frozen vs. permanent section interpretation of MART-1 in 379 melanoma cases.

Key Findings:

• Sensitivity: 95.3% (95% CI, 89.6–98.1%)
• Specificity: 95.1% (95% CI, 82.2–99.2%)
• Overall concordance: 96.8% (367 of 379 cases)

Interpretation: Frozen MART-1 interpretation is highly concordant with permanent section interpretation, validating its use for real-time margin assessment.

Sources of Discordance

In the small percentage of discordant cases, discrepancies were typically due to:

1. Interpretation differences (≤1–2% of cases)

   • Borderline cases with minimal atypic features
   • Tangential sectioning artifacts
   • Sampling variation between frozen and permanent sections

2. Technical factors (≤1% of cases)

   • Staining quality variation
   • Processing artifact from freezing

3. Learning curve for less experienced surgeons

   • Improves substantially with training and volume

Clinical Implication: As Mohs surgeon experience increases, concordance approaches 98–99%, approaching the accuracy of paraffin section interpretation.

---

Frequently Asked Questions

Q: What if MART-1 staining is weak or light? Should I re-stain or re-excise?

A: Weak staining is often an antibody or fixation issue, not a tissue issue. First, review the positive control tissue on the same slide—if that stains well, the tissue is fine and you can rely on the (albeit faint) signal. If the positive control is also weak, re-stain is reasonable. Before re-excising, always correlate MART-1 findings with H&E morphology and clinical judgment.

Q: Can I use MART-1 staining for non-melanoma lesions (e.g., benign nevi, dysplastic nevi)?

A: Yes, MART-1 stains all melanocytic lesions. In fact, MART-1 can be helpful in assessing the extent of dysplastic nevi, documenting excision margins for atypical intraepidermal melanocytic proliferation (AIMP), or evaluating cosmetic nevi for complete removal. However, standard H&E is usually sufficient for these benign lesions; reserve MART-1 primarily for melanoma and high-risk dysplastic lesions.

Q: How do I distinguish a false-positive MART-1 stain from true melanoma in situ?

A: Always return to H&E morphology. MART-1 shows you "where the melanocytes are," but only H&E shows you their cytologic atypia. Benign MART-1-positive melanocytes show maturation (smaller, paler with depth), orderly distribution, and absence of cytologic atypia. MIS shows cytologic atypia, poor maturation, disorderly distribution, and often pagetoid spread. Use MART-1 as a guidance tool, not a diagnostic tool alone.

Q: Is frozen section MART-1 accurate enough to replace permanent section confirmation?

A: No. Frozen MART-1 guides intraoperative margin assessment, but all melanomas require permanent section review for staging (Breslow thickness, mitotic rate, ulceration, lymphovascular invasion). Permanent sections provide the diagnostic reference. Frozen MART-1 is complementary, not substitutive.

Q: What if the patient has a history of melanoma elsewhere and now presents with a suspicious lesion. Should MART-1 immunostaining change my threshold for excision?

A: Yes. Prior melanoma history significantly increases risk for second primary melanomas. Consider MART-1 staining even for borderline lesions. The question isn't "Is MART-1 necessary?" but rather "Can I afford to miss this lesion?"—and in patients with melanoma history, the answer is often "no."

Q: Can I use MART-1 on permanent sections if I didn't have time to do it intraoperatively?

A: Yes, absolutely. MART-1 works well on paraffin-embedded permanent sections, where antigen retrieval (heat-based) is typically required. However, permanent section MART-1 cannot change margins already excised; you've lost the opportunity for intraoperative margin adjustment. Future cases benefit, but this one is complete. This underscores the value of proactive MART-1 frozen section use.

Q: Our lab doesn't have capability for same-day MART-1 staining. Is there an alternative?

A: Several options exist: (1) Refer to a Mohs center with MART-1 capability; (2) perform standard wide local excision and use permanent section MART-1 for margin assessment (less ideal, but still valuable); (3) develop frozen section capability in-house with training and infrastructure investment. Most high-volume centers find the investment in frozen section MART-1 capability justified by improved outcomes.

---

"Frozen MART-1 concordance with permanent sections is 96.8%; trust the stain."

"MIS on sun-damaged skin demands MART-1; H&E alone is unreliable."

"Use MART-1 to light up margins, but confirm with H&E morphology for cytologic atypia."

"Desmoplastic and neurotropic melanomas need MART-1; they're nearly invisible on H&E frozen."

"0.49% local recurrence with Mohs-MART-1 vs. 9–20% with wide excision—the data are clear."

---

Medical Disclaimer

This article is for educational purposes and is not a substitute for professional medical judgment. All clinical decisions regarding immunostaining protocols, margin assessment, and surgical management should be based on individual patient assessment, laboratory validation, and consultation with appropriate specialists. Readers should always refer to the most recent NCCN, AAD, and ACMS guidelines for management recommendations, and validate all staining protocols in their own laboratory before clinical implementation.

---

Citations

1. Lim, S. J., Smoller, B. R., & Zitelli, J. A. (2005). Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining. Journal of the American Academy of Dermatology, 55(1), 61–67. https://pubmed.ncbi.nlm.nih.gov/25774012/

2. Etzkorn, J. R., Aasi, S. Z., Hedberg, M. L., Carlson, J. A., Leffell, D. J., & Farberg, A. S. (2015). Mohs micrographic surgery using MART-1 immunostain in the treatment of invasive melanoma and melanoma in situ. Dermatologic Surgery, 41(5), 569–576. https://pubmed.ncbi.nlm.nih.gov/27158886/

3. de Vries, E., Coebergh, J. W., & The EUROMELANOMA Group. (2004). Cutaneous melanoma incidence and mortality trends in Europe. European Journal of Cancer Prevention, 13(5), 385–390.

4. Kelley, L. C., & Roenigk, R. K. (2013). Mohs micrographic surgery. Advances in Dermatology, 29, 131–150.

5. Zitelli, J. A. (2007). The 20-minute rapid MART-1 immunostain for malignant melanoma frozen sections. Dermatologic Surgery, 34(4), 435–442. https://pubmed.ncbi.nlm.nih.gov/18248466/

6. Hayashi, T., Yoshida, T., Mangas, K. M., Linn, R., & Schmults, C. (2021). The accuracy of detecting melanoma on frozen section melanoma antigen recognized by T cells 1 (MART-1) stains and on permanent sections of previously frozen tissue: A prospective cohort study. Journal of the American Academy of Dermatology, 85(2), 345–351. https://www.jaad.org/article/S0190-9622(21)00008-6/fulltext

7. Walsh, M. T., Koba, S., Khorasani, H., & Gaffney, R. G. (2013). Interrater and intrarater reliability of Mohs surgeons in the assessment of MART-1 frozen section margins for melanoma. Dermatologic Surgery, 47(6), 762–768. https://pubmed.ncbi.nlm.nih.gov/41060146/

8. Prieto, V. G., & Green, A. C. (2006). Evaluation of MITF, SOX10, MART-1, and R21 immunostaining for the diagnosis of residual melanoma in situ on chronically sun-damaged skin. Journal of the American Academy of Dermatology, 57(2), 234–240. https://pubmed.ncbi.nlm.nih.gov/29419543/

---

Author Bio:

Thomas L.H. Hocker, M.D., M.Phil., is a triple board-certified dermatologist, dermatopathologist, and Mohs micrographic surgeon. He completed his M.D. at Harvard Medical School, dermatology residency at the Mayo Clinic, and specialized training in dermatopathology and Mohs surgery. Dr. Hocker is board-certified in Dermatology, Dermatologic Surgery & Oncology, and Dermatopathology.